Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;77(4):588-600.
doi: 10.1111/his.14190. Epub 2020 Sep 12.

When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases

Matthew Zaborowski  1   2 , Ana C Vargas  1   3   4 , Jeremy Pulvers  1   2 , Adele Clarkson  1   2 , Danica de Guzman  1   2 , Loretta Sioson  1   2 , Fiona Maclean  1   3   5 , Angela Chou  1   2   4 , Anthony J Gill  1   2   4
Affiliations

When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases

Matthew Zaborowski et al. Histopathology. 2020 Oct.

Abstract

Aims: Synovial sarcoma is defined by recurrent t(X;18)(p11;q11) translocations creating SS18-SSX1, SS18-SSX2 or SS18-SSX4 fusions. Recently, a novel rabbit monoclonal antibody designed to identify these fusions (SS18-SSX, clone E9X9V) was proposed to be highly specific (100%), but not completely sensitive (95%) for this diagnosis. Another antibody designed to identify the C-terminal end of SSX (SSX_CT, clone E5A2C) was proposed to be highly sensitive (100%), but not completely specific (96%). We sought to validate these antibodies in an independent cohort.

Methods and results: We performed immunohistochemistry for SS18-SSX and SSX_CT on 39 synovial sarcoma samples from 25 patients with confirmed gene rearrangements. Thirty-four (87%) and 36 (92%) were positive for SS18-SSX and SSX_CT, respectively. False-negative staining was associated with suboptimally handled small biopsies and decalcified specimens, even when staining was diffuse and strong in subsequent optimally processed excisions and non-decalcified areas. None of 580 non-synovial sarcoma tumours (76 whole sections, 504 TMA samples) were positive for SS18-SSX (100% specificity), whereas 39 (93% specificity) were positive for SSX_CT.

Conclusions: SS18-SSX fusion-specific IHC is 87-95% sensitive for the diagnosis of synovial sarcoma and highly (perhaps perfectly) specific. Therefore, positive SS18-SSX staining definitively confirms the diagnosis of synovial sarcoma. SSX_CT is less specific (93-96%) but highly sensitive (92%, but approaching 100% when suboptimally processed biopsies and decalcified specimens are excluded). Negative SSX_CT staining may therefore have an ancillary role as a rule-out test for synovial sarcoma. We caution that both antibodies are prone to false-negative staining in decalcified specimens.

Keywords: E5A2C; E9X9V; SS18-SSX; SSX_CT; synovial sarcoma.

PubMed Disclaimer

References

    1. Bessen T, Caughey GE, Shakib S et al. A population-based study of soft tissue sarcoma incidence and survival in Australia: an analysis of 26,970 cases. Cancer Epidemiol. 2019; 63; 101590.
    1. Sultan I, Rodriguez-Galindo C, Saab R et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005. Cancer 2009; 115; 3535-3547.
    1. Svejstrup JQ. Synovial sarcoma mechanisms: a series of unfortunate events. Cell 2013; 153; 11-12.
    1. Alfert A, Moreno N, Kerl K. The BAF complex in development and disease. Epigenet. Chromatin 2019; 12; 19.
    1. McBride MJ, Pulice JL, Beird HC et al. The SS18-SSX fusion oncoprotein hijacks BAF complex targeting and function to drive synovial sarcoma. Cancer Cell 2018; 33; 1128-1141.

MeSH terms

Grants and funding

LinkOut - more resources